BR112012026219A2 - método diagnósticos para glaucoma - Google Patents
método diagnósticos para glaucomaInfo
- Publication number
- BR112012026219A2 BR112012026219A2 BR112012026219A BR112012026219A BR112012026219A2 BR 112012026219 A2 BR112012026219 A2 BR 112012026219A2 BR 112012026219 A BR112012026219 A BR 112012026219A BR 112012026219 A BR112012026219 A BR 112012026219A BR 112012026219 A2 BR112012026219 A2 BR 112012026219A2
- Authority
- BR
- Brazil
- Prior art keywords
- glaucoma
- analysis
- diagnostic
- diagnostic method
- sample
- Prior art date
Links
- 208000010412 Glaucoma Diseases 0.000 title abstract 8
- 238000002405 diagnostic procedure Methods 0.000 title abstract 5
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 238000004458 analytical method Methods 0.000 abstract 4
- 210000001124 body fluid Anatomy 0.000 abstract 4
- 239000010839 body fluid Substances 0.000 abstract 4
- 238000012606 in vitro cell culture Methods 0.000 abstract 3
- 230000001363 autoimmune Effects 0.000 abstract 2
- 230000009257 reactivity Effects 0.000 abstract 2
- 230000003833 cell viability Effects 0.000 abstract 1
- 238000011534 incubation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/168—Glaucoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rehabilitation Therapy (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Rheumatology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
método diagnósticos para glaucoma. a presente invenção refere-se a um primeiro método diagnóstico para glaucoma com base em uma análise da reatividade autoimune em fluidos corporais contra pelo menos uma amostra de antígenos oculares pelo menos parcialmente purificados, em que a reatividade autoimune contra antígenos individuais é medida e transformada em um escore de glaucoma para determinar o resultado diagnóstico. outros aspectos da invenção incluem elementos portadores de antígeno que trazem pelo menos uma amostra dos antígenos oculares pelo menos parcialmente purificados e kits para o diagnóstico de glaucoma. outros aspectos incluem métodos de coleta de um fluido corporal, tais como lágrimas, para a utilização no método diagnóstico para o glaucoma. ainda outros aspectos incluem antígenos oculares que servem como marcadores diagnósticos e/ ou para o preparo de composições farmacêuticas para o tratamento de glaucoma. a invenção diz ainda respeito a um segundo método diagnóstico para glaucoma compreendendo as etapas de: a) fornecimento de uma cultura de células in vitro, b) incubação de um fluido corporal de um indivíduo teste com a cultura de células in vitro ou componentes de incubação, os quais são francionados a partir do fluido corporal ou de uma amostra corporal do indivíduo de teste com a cultura de células in vitro, c) análise da expressão de protéina das células e/ ou análise da viabilidade das células após o tratamento de acordo com a etapa b) e d) comparação dos resultados da análise na etapa c) com os dados padrões para determinar um resultado diagnóstico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34236310P | 2010-04-13 | 2010-04-13 | |
| PCT/CH2011/000077 WO2011127616A1 (en) | 2010-04-13 | 2011-04-13 | Diagnostic methods for glaucoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112012026219A2 true BR112012026219A2 (pt) | 2016-07-12 |
| BR112012026219B1 BR112012026219B1 (pt) | 2019-12-10 |
Family
ID=43984128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012026219A BR112012026219B1 (pt) | 2010-04-13 | 2011-04-13 | método para o diagnóstico de glaucoma, elementos carreadores de antígeno e kit |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10175251B2 (pt) |
| EP (1) | EP2558862B1 (pt) |
| JP (2) | JP2013529292A (pt) |
| KR (1) | KR101903193B1 (pt) |
| CN (1) | CN103003693B (pt) |
| AU (1) | AU2011241402B2 (pt) |
| BR (1) | BR112012026219B1 (pt) |
| CA (1) | CA2795270C (pt) |
| DK (1) | DK2558862T3 (pt) |
| ES (1) | ES2712060T3 (pt) |
| HR (1) | HRP20190278T1 (pt) |
| HU (1) | HUE042703T2 (pt) |
| PL (1) | PL2558862T3 (pt) |
| RU (1) | RU2657515C2 (pt) |
| TR (1) | TR201902542T4 (pt) |
| WO (1) | WO2011127616A1 (pt) |
| ZA (1) | ZA201207935B (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140147413A1 (en) * | 2011-02-28 | 2014-05-29 | Dong Feng Chen | Therapies That Target Autoimmunity For Treating Glaucoma And Optic Neuropathy |
| US20150019136A1 (en) * | 2012-02-21 | 2015-01-15 | The Regents Of The University Of California | Systems and methods for determining retinal ganglion cell populations and associated treatments |
| EP2770326B1 (en) * | 2013-02-26 | 2019-09-11 | Instituto Oftalmologico Fernandez - Vega, S.L. | Method for the diagnosis of glaucoma based on the determination of serum protein levels |
| US20170224771A1 (en) * | 2014-10-15 | 2017-08-10 | Rapid Pathogen Screening, Inc. | Histatins as therapeutic agents for ocular surface disease |
| JP6499918B2 (ja) | 2015-05-20 | 2019-04-10 | 株式会社トプコン | 眼科検査支援システム及び眼科検査支援サーバ |
| RU2617066C1 (ru) * | 2016-04-01 | 2017-04-19 | Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ определения показаний к интравитреальному введению цилиарного нейротрофического фактора при лечении заболеваний зрительно-нервного аппарата глаза |
| US11369695B2 (en) | 2016-12-05 | 2022-06-28 | The Jackson Laboratory | Fat droplets in retina and optic nerve as a diagnostic marker for neurodegeneration and glaucoma in humans |
| JP7202609B2 (ja) * | 2017-12-13 | 2023-01-12 | 国立大学法人東北大学 | 視神経障害の診断用バイオマーカー |
| CN108229545B (zh) * | 2017-12-22 | 2021-09-14 | 北京市商汤科技开发有限公司 | 青光眼诊断的方法、装置及电子设备 |
| CN111856037B (zh) * | 2020-07-31 | 2021-06-22 | 四川大学华西第二医院 | Unc45a与hsp10的比值在pop早期预警、诊断、预后评估中的应用和产品 |
| KR102596340B1 (ko) | 2020-08-25 | 2023-11-02 | 사회복지법인 삼성생명공익재단 | 안질환 시야 손상 예후 예측 시스템 및 방법과 이를 위한 컴퓨터 프로그램 |
| CN113444789A (zh) * | 2021-08-27 | 2021-09-28 | 中国医学科学院北京协和医院 | 青光眼相关生物标志物及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9419267D0 (en) | 1994-09-23 | 1994-11-09 | Unilever Plc | Assay devices |
| RU2187983C2 (ru) | 1998-11-10 | 2002-08-27 | Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" | Способ диагностики характера течения глаукомы |
| US20030149997A1 (en) | 1999-02-19 | 2003-08-07 | Hageman Gregory S. | Diagnostics and therapeutics for arterial wall disruptive disorders |
| US20020102581A1 (en) * | 1999-02-19 | 2002-08-01 | Hageman Gregory S. | Diagnostics and therapeutics for ocular disorders |
| US7011952B2 (en) * | 2000-02-22 | 2006-03-14 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
| ES2316446T3 (es) | 2000-04-29 | 2009-04-16 | University Of Iowa Research Foundation | Diagnostico y terapeutica para trastornos relacionados con la degeneracion macular. |
| CN1393470A (zh) * | 2001-06-29 | 2003-01-29 | 上海博德基因开发有限公司 | 一种多肽——beta转导素－45.65和编码这种多肽的多核苷酸 |
| ATE526041T1 (de) * | 2001-12-11 | 2011-10-15 | Fibrogen Inc | Verfahren zur hemmung okularer vorgänge |
| JP2006506970A (ja) * | 2002-07-12 | 2006-03-02 | ユニバーシティ オブ ワシントン | 神経細胞の延長されたインビトロ培養のための方法および系 |
| WO2004036220A1 (en) | 2002-10-18 | 2004-04-29 | Rescom Gmbh | Diagnosis of glaucoma by complex autoantibody repertoires in body fluids |
| US7662389B2 (en) * | 2003-12-17 | 2010-02-16 | Alcon, Inc. | Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents |
| KR101329369B1 (ko) | 2003-12-19 | 2013-11-14 | 오메가 바이오 파마(아이.피.3) 리미티드 | 당뇨 치료용 조성물 및 방법 |
| JP2009502954A (ja) * | 2005-07-27 | 2009-01-29 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド | タンパク質のミスフォールディングを修正する小分子及びその使用 |
| EP1832600A1 (en) * | 2006-03-09 | 2007-09-12 | Max-Delbrück-Centrum Für Molekulare Medizin | Peptides against autoantibodies associated with glaucoma and use of these peptides |
| RU2314535C1 (ru) | 2006-07-05 | 2008-01-10 | Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по здравоохранению и социальному развитию" | Способ диагностики начальной стадии открытоугольной глаукомы |
| CN101490550A (zh) | 2006-07-08 | 2009-07-22 | 肯塔基大学研究基金会 | 肺癌诊断分析 |
| EP1929937A1 (de) * | 2006-12-07 | 2008-06-11 | F. Hoffmann-Roche AG | Vorrichtung und Verfahren zum Untersuchen von Körperflüssigkeiten |
| RU2371721C2 (ru) | 2007-06-25 | 2009-10-27 | Закрытое акционерное общество "Молекулярно-медицинские технологии" | Устройство для диагностики с использованием биочипов |
| GB0724412D0 (en) * | 2007-12-14 | 2008-02-06 | Ucl Business Plc | Marker |
| KR101188439B1 (ko) * | 2008-04-02 | 2012-10-08 | (주)루미아이제네틱스 | 녹내장 진단용 키트 |
| EP2354792A1 (en) | 2010-02-08 | 2011-08-10 | Biomonitor A/S | Method for detecting anti-drug antibodies |
| KR20100087276A (ko) | 2010-07-21 | 2010-08-04 | (주)루미아이제네틱스 | 녹내장 진단용 키트 |
| KR20100087275A (ko) | 2010-07-21 | 2010-08-04 | (주)루미아이제네틱스 | 녹내장 진단용 키트 |
-
2011
- 2011-04-13 JP JP2013504084A patent/JP2013529292A/ja active Pending
- 2011-04-13 BR BR112012026219A patent/BR112012026219B1/pt active IP Right Grant
- 2011-04-13 AU AU2011241402A patent/AU2011241402B2/en active Active
- 2011-04-13 EP EP11714916.1A patent/EP2558862B1/en active Active
- 2011-04-13 ES ES11714916T patent/ES2712060T3/es active Active
- 2011-04-13 DK DK11714916.1T patent/DK2558862T3/en active
- 2011-04-13 KR KR1020127029751A patent/KR101903193B1/ko active IP Right Grant
- 2011-04-13 PL PL11714916T patent/PL2558862T3/pl unknown
- 2011-04-13 HU HUE11714916A patent/HUE042703T2/hu unknown
- 2011-04-13 RU RU2012147551A patent/RU2657515C2/ru active
- 2011-04-13 CA CA2795270A patent/CA2795270C/en active Active
- 2011-04-13 US US13/641,009 patent/US10175251B2/en active Active
- 2011-04-13 TR TR2019/02542T patent/TR201902542T4/tr unknown
- 2011-04-13 CN CN201180028608.XA patent/CN103003693B/zh active Active
- 2011-04-13 WO PCT/CH2011/000077 patent/WO2011127616A1/en active Application Filing
-
2012
- 2012-10-22 ZA ZA2012/07935A patent/ZA201207935B/en unknown
-
2015
- 2015-12-25 JP JP2015253808A patent/JP6225157B2/ja active Active
-
2019
- 2019-02-11 HR HRP20190278TT patent/HRP20190278T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10175251B2 (en) | 2019-01-08 |
| DK2558862T3 (en) | 2019-03-18 |
| EP2558862A1 (en) | 2013-02-20 |
| AU2011241402A1 (en) | 2012-11-15 |
| ZA201207935B (en) | 2019-07-31 |
| RU2657515C2 (ru) | 2018-06-14 |
| RU2012147551A (ru) | 2014-05-20 |
| CA2795270A1 (en) | 2011-10-20 |
| ES2712060T3 (es) | 2019-05-09 |
| CN103003693A (zh) | 2013-03-27 |
| TR201902542T4 (tr) | 2019-03-21 |
| HRP20190278T1 (hr) | 2019-04-19 |
| EP2558862B1 (en) | 2018-11-21 |
| KR101903193B1 (ko) | 2018-10-01 |
| BR112012026219B1 (pt) | 2019-12-10 |
| PL2558862T3 (pl) | 2019-07-31 |
| JP2016048265A (ja) | 2016-04-07 |
| US20130172204A1 (en) | 2013-07-04 |
| WO2011127616A1 (en) | 2011-10-20 |
| HUE042703T2 (hu) | 2019-07-29 |
| CA2795270C (en) | 2021-06-08 |
| AU2011241402B2 (en) | 2016-09-15 |
| CN103003693B (zh) | 2016-07-06 |
| JP2013529292A (ja) | 2013-07-18 |
| KR20130122706A (ko) | 2013-11-08 |
| JP6225157B2 (ja) | 2017-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012026219A2 (pt) | método diagnósticos para glaucoma | |
| AR107561A2 (es) | Ensayo elisa para la detección de vegf | |
| RU2014117161A (ru) | Композиции и способы испытаний на токсикогенность | |
| Kang et al. | Relation between time spent outdoors and exfoliation glaucoma or exfoliation glaucoma suspect | |
| Urizar-Arenaza et al. | Phosphoproteomic and functional analyses reveal sperm-specific protein changes downstream of kappa opioid receptor in human spermatozoa | |
| IN2014MN02060A (pt) | ||
| PH12015500519A1 (en) | Mitochondrial toxicity test | |
| Xu et al. | Mycobacterium tuberculosis infection up-regulates MFN2 expression to promote NLRP3 inflammasome formation | |
| MA38042A2 (fr) | Méthylglyoxal en tant que marqueur du cancer | |
| Mitra et al. | Vaccination against histomonosis limits pronounced changes of B cells and T-cell subsets in turkeys and chickens | |
| Ünsel et al. | Diagnostic value of specific IgE analysis in latex allergy | |
| Lei et al. | Endothelial nitric oxide synthase–related mechanotransduction changes in aged porcine angular aqueous plexus cells | |
| Sauer et al. | Circulating hyaluronic acid signature in CAP and ARDS–the role of pneumolysin in hyaluronic acid shedding | |
| Labelle et al. | Effects of ophthalmic disease on concentrations of plasma fibrinogen and serum amyloid A in the horse | |
| EA201490576A1 (ru) | Молекулярный маркер для ранней диагностики мезотелиомы плевры у пациентов и способы для анализа его экспрессии | |
| Parikh et al. | Proteomic analyses of corneal tissue subjected to alkali exposure | |
| BR112018008928A2 (pt) | um método ex vivo para testar a capacidade de resposta celular de populações de células primárias a um fármaco ou combinação de fármacos | |
| BR112012027535A2 (pt) | método para a detecção da susceptibilidade em desenvolver efeitos colaterais adversos relacionados com bioimplantes | |
| CN110487646A (zh) | 一种体外检测血管收缩功能的方法 | |
| Gomez | 112: EFFECTS OF BROWN RICE (ORYZA SATIVA) IN THE DIETARY MANAGEMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS | |
| CN110527721A (zh) | 一种陈旧性结核病标志物及其应用 | |
| Jiang et al. | First proficiency testing of second-line anti-tuberculosis drug susceptibility testing in 12 provinces of China | |
| Nurpeysova et al. | Preclinical testing of Kazfluvac, a vaccine against pandemic influenza A/H5N1v | |
| RU2009101693A (ru) | Способ определения тяжести заболевания и эффективности лечения у больных бронхолегочными заболеваниями | |
| Szeredi et al. | Comparative examination of a rapid immunocytochemical test for the detection of highly pathogenic avian influenza virus in domestic birds in field outbreaks |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: M-LAB AG (CH) |
|
| B25A | Requested transfer of rights approved |
Owner name: M-LAB GMBH (DE) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/04/2011, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/04/2011, OBSERVADAS AS CONDICOES LEGAIS |